Get the Stockscreener App
0.95
5.94%
-0.06
After Hours:
.97
0.02
+2.11%
Estrella Immunopharma Inc stock is traded at $0.95, with a volume of 51,505.
It is down -5.94% in the last 24 hours and down -15.18% over the past month.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
See More
Previous Close:
$1.01
Open:
$1.03
24h Volume:
51,505
Relative Volume:
0.63
Market Cap:
$40.88M
Revenue:
-
Net Income/Loss:
$-13.06M
P/E Ratio:
-2.6603
EPS:
-0.3571
Net Cash Flow:
$-1.79M
1W Performance:
-12.04%
1M Performance:
-15.18%
6M Performance:
-39.87%
1Y Performance:
+2.00%
1-Day Range:
$0.95
$1.03
1-Week Range:
$0.95
$1.11
52-Week Range:
$0.78
$3.15
Estrella Immunopharma Inc Stock (ESLA) Company Profile
Name
Estrella Immunopharma Inc
Sector
Industry
Phone
(510) 318-9098
Address
5858 HORTON STREET, SUITE 370, EMERYVILLE
Compare ESLA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
0.95 | 40.88M | 0 | -13.06M | -1.79M | -0.3571 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Estrella Immunopharma Inc Stock (ESLA) Latest News
Estrella Immunopharma Inc. (ESLA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Estrella Immunopharma Inc (ESLAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Estrella Immunopharma Inc (ESLAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Estrella Immunopharma Inc - TradingKey
Estrella Immunopharma Inc (ESLAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Estrella Immunopharma Inc (ESLAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Estrella Immunopharma Inc (ESLAW) Institutional Confidence - TradingKey
Estrella Immunopharma Inc (ESLA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Estrella Immunopharma Inc (ESLAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Estrella Immunopharma Inc (ESLA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Estrella Immunopharma Inc (ESLAW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Estrella Immunopharma Inc (ESLA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Estrella Immunopharma Inc. (ESLA) Q1 2026 Earnings: Miss on EPS as Pre-Revenue Biotech Navigates Clinical DevelopmentEarnings Surprise Stocks - newsline.com
Estrella Immunopharma (ESLA) Edges Higher Amid Broader Biotech SentimentWyckoff Accumulation - newsline.com
ESLAW Warrants Slide 13% as Support at $0.10 Faces Critical TestStop Hunt - newsline.com
ESLA Q1 2026 Earnings: Wider Loss Than Expected Amid Pre-Revenue Development StageEPS Revision Trend - newsline.com
ESLA Q1 2026 Earnings: EPS Misses Estimates by Wide Margin as Stock Rises 10.6%Earnings Sentiment Score - newsline.com
ESLA Q1 2026 Earnings: Wider-than-Expected Loss as Pre-revenue Biotech Continues DevelopmentEarnings Revision Report - The Legal Advocate
Estrella Immunopharma Warrant (ESLAW) Holds Steady at $0.13 – Consolidation Narrows Trading RangeAD Line Divergence - newsline.com
Estrella Immunopharma (ESLA) Edges Lower Near Support as Biotech Sector Faces HeadwindsMutual Fund Flow - The Legal Advocate
ESLAW Surges 22.52%: Estrella Immunopharma Warrant Breaks Above SupportVolatility Surface - The Legal Advocate
Estrella Immunopharma Inc. (ESLA) Shows Modest Uptick Amid Sector StabilityLinear Regression - The Legal Advocate
Estrella Immunopharma (ESLA) sets virtual 2026 meeting to ratify auditor - Stock Titan
Estrella Immunopharma Warrant (ESLAW) Surges 18.85% to $0.10, Faces Key Resistance at $0.11Volume Breadth - The Legal Advocate
Estrella Immunopharma (ESLA) Q1 2026 Earnings: Wider-Than-Expected Loss Triggers Modest Stock GainLow Growth Earnings - Newser
ESLA Q1 2026 Earnings: Wider-Than-Expected Loss and No Revenue Highlight Development-Stage Challenges - newsline.com
Estrella Immunopharma (ESLA) Q1 2026 Earnings Slump: EPS Falls Short of $-0.18 TargetHigh Interest Stocks - Newser
Estrella Immunopharma, Inc. 2026 Q1 Financial Report: Key Financials, Related Party Transactions, and R&D Update - Minichart
Estrella Immunopharma (ESLA) Q1 2026 Earnings Miss by Significant: Key TakeawaysEPS Growth Rate - Newser
Estrella Immunopharma, Inc. 1Q 2026: Net income $(2.29M), EPS $(0.05) — 10-Q Summary - TradingView
Estrella Immunopharma (ESLA) Stock Analysis: Falls -6.22%, Watching $1.07 2026-05-15Popular Market Picks - newser.com
[SCHEDULE 13G] Estrella Immunopharma, Inc. Passive Investment Disclosure (>5%) - Stock Titan
TradingKey - TradingKey
The quiet positioning of Estrella (ESLAW) nobody discusses (Moonwalks) 2026-05-08Bullish Pattern - newser.com
Estrella Immunopharma (ESLA) Q1 loss deepens, EPS miss of 90.6 percent rattles investor confidence.Special Dividend Alert - The Legal Advocate
Estrella Immunopharma (ESLA) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference - BioSpace
10-K/A: Annual report (Amendment) - Moomoo
Is Estrella (ESLAW) stock a safe investment |EBITDA Margin Trends - newsline.com
Eureka-led Estrella (NASDAQ: ESLA) details 59.3% control and board pay - Stock Titan
Estrella Immunopharma CFO Xu Jiandong buys $2,594 in stock - Investing.com
Estrella Immunopharma CFO Xu Jiandong buys $2,594 in stock By Investing.com - Investing.com Canada
Estrella Immunopharma (ESLA) CFO boosts stake with small share buys - Stock Titan
ESLA Estrella Immunopharma falls 3.92% after Q1 2026 EPS misses analyst forecasts by a wide 90.6% margin.Growth Phase - newser.com
Is Estrella (ESLAW) stock a good option for investors |High Volatility - newser.com
Estrella Immunopharma (ESLA) Stock: Changing Trend? (Institutional Selling) 2026-04-27News Sentiment - newsline.com
Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Declines By 57.6% - MarketBeat
OneIM Acquisition Corp. (OIM) - Minichart
Estrella Immunopharma (ESLA) Management Strategy | Q1 2026: Below ExpectationsStrong Sell - Cổng thông tin điện tử tỉnh Tây Ninh
Robinson Opportunistic Income Fund's Estrella Immunopharma Inc(ESLAW) Holding History - GuruFocus
Estrella Immunopharma Inc Stock (ESLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):